Nasdaq – Talk Bio

Eikon and Veradermics Announce IPO Targets Amid Biotech Market Optimism

14 hours ago talkbio0Tagged Alopecia, cancer drugs, Eikon, IPO, Nasdaq, NYSE, Veradermics

Eikon Therapeutics; Veradermics; IPO; biotech; hair loss; cancer drugs; Nasdaq; NYSE

2026 IPO Train Keeps Chugging as AgomAb Therapeutics and SpyGlass Pharma File for Nasdaq Debuts

2 weeks ago talkbio0Tagged AgomAb, bimatoprost IOL, Biotech IPOs, IPO, Nasdaq, ontunisertib, SpyGlass Pharma (

AgomAb Therapeutics; SpyGlass Pharma; IPO; Nasdaq; 2026 biotech IPOs; ontunisertib; bimatoprost IOL

MapLight Therapeutics Announces Pricing of $17/share IPO; to Raise Over $250 Million, Begins Trading on Nasdaq

3 months ago talkbio0Tagged Alzheimer 's disease, biotech, CNS disorder, IPO, MapLight Therapeutics, MPLT, Nasdaq, Phase 2 Clinical Trials, Psychotic Disorders, Public Offering, Schizophrenia

MapLight Therapeutics; IPO; Initial Public Offering; Nasdaq; MPLT; Schizophrenia; Alzheimer’s disease psychosis; CNS disorders; Phase 2 clinical trials; Biotech

LB Pharmaceuticals Upsizes IPO to $285M, Marks First Major Biotech Listing in Months

5 months ago talkbio0Tagged IPO, IPOs, LBRX, Nasdaq, Phase III, Pounds, public entity, Schizophrenia

LB Pharmaceuticals; IPO; biotech; $285 million; LBRX; schizophrenia; Phase III; public offering; Nasdaq; 2025 biotech IPOs

LB Pharmaceuticals Files for $228M IPO to Fund Phase III Schizophrenia Drug

5 months ago talkbio0Tagged Alzheimer 's psychosis, amisulpride, Clinical Nurse Specialists, Depression, Bipolar, IPO, LB-102, Nasdaq, Phase 3 Clinical Trials, Pounds, Schizophrenia, United States Food and Drug Administration

LB Pharmaceuticals; IPO; Phase III trial; schizophrenia; LB-102; biotech; CNS therapeutics; bipolar depression; Alzheimer’s psychosis; amisulpride; FDA; Nasdaq